Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,661 public trials 325 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Active, Not Recruiting

A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

NCT04133636

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University Of California San Diego San Diego, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Yale University School Of Medicine New Haven, Connecticut, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 47 locations
View Trial Details
Active, Not Recruiting

A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

NCT04910568

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • City of Hope Duarte, California, United States
  • City of Hope - Lennar Foundation Cancer Center Irvine, California, United States
  • Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center Denver, Colorado, United States
  • Karmanos Cancer Institute. Detroit, Michigan, United States
View all 24 locations
View Trial Details
Active, Not Recruiting

Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00602641

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Providence Hospital Mobile, Alabama, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Sparks Regional Medical Center Fort Smith, Arkansas, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
View all 391 locations
View Trial Details
Active, Not Recruiting

DARA RVD For High Risk SMM

NCT04775550

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Stamford Hospital Stamford, Connecticut, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Dana-Farber Brigham Cancer Center - Foxborough Foxborough, Massachusetts, United States
View Trial Details
Active, Not Recruiting

A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma

NCT05827016

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Rocky Mountain Cancer Centers Aurora, Colorado, United States
  • Mayo Clinic Hospital - Florida Jacksonville, Florida, United States
  • Local Institution - 0308 Tampa, Florida, United States
  • H. Lee Moffitt Cancer Center & Research Institute Tampa, Florida, United States
View all 271 locations
View Trial Details
Active, Not Recruiting

Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

NCT04162210

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Tucson, Arizona, United States
  • GSK Investigational Site Pueblo, Colorado, United States
  • GSK Investigational Site Detroit, Michigan, United States
  • GSK Investigational Site Omaha, Nebraska, United States
View all 136 locations
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Nirogacestat, Pomalidomide, and Dexamethasone in Participants With RRMM

NCT07150104

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Salvador, Estado de Bahia, Brazil
  • GSK Investigational Site Porto Alegre, Rio Grande do Sul, Brazil
  • GSK Investigational Site Halifax, Nova Scotia, Canada
  • GSK Investigational Site Villejuif, France
View Trial Details
Active, Not Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM

NCT07217184

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • GSK Investigational Site Atlanta, Georgia, United States
  • GSK Investigational Site Boston, Massachusetts, United States
  • GSK Investigational Site Grand Rapids, Michigan, United States
  • GSK Investigational Site Madison, Wisconsin, United States
View all 19 locations
View Trial Details
Active, Not Recruiting

Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

NCT01562405

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Emory University Atlanta, Georgia, United States
  • Massachusetts General Hosptial Boston, Massachusetts, United States
  • Brigham and Women's Hospital Boston, Massachusetts, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details

Related conditions